OBJECTIVES: Immune thrombocytopenia (ITP) is a rare autoimmune disorder characterised by low platelet counts resulting in symptoms that are usually minor, e.g. petechiae. However, patients with very low platelet counts face the risk of serious, but rare, bleeds, e.g. intracranial hemorrhage. The study objective was to estimate the cost-effectiveness of treating two groups of chronic adult ITP patients (refractory to splenectomy and where splenectomy is contraindicted) with oral eltrombopag versus romiplostim or rituximab from an Irish health care payer perspective. METHODS: A Markov model with a four week model cycle, two year time horizon and seven health states was used. In one arm, patients were treated with eltrombopag and in the other romiplostim or rituximab. Patients began in either the 'controlled platelet' or 'uncontrolled platelet' health states. Response rates from clinical trials (eltrombopag and romiplostim) and a published literature review (rituximab) determined whether patients were controlled or not. Controlled patients experienced a higher level of utility and lower risk of transitioning to bleed health states. Utilities (using the SF-36v2) for controlled/uncontrolled platelet levels were from the eltrombopag pivotal trial, RAISE. Utility for bleeds and costs were taken from the literature. Costs and benefi ts were discounted by 4%. RESULTS: The model estimated that eltrombopag dominates romiplostim, i.e. cost savings of c13,000 and c18,000 with an incremental QALY of 0.1 and 0.03 for patients who are refractory to splenectomy and where splenectomy is contraindicated respectively. This result was driven by the fact that eltrombopag is less expensive, does not incur wastage or administration costs and has slightly better durable response rates compared to romiplostim. Eltrombopag is not cost-effective compared to rituximab for both groups of patients because rituximab is signifi cantly less costly than eltrombopag with comparable response rates. CONCLUSIONS: The economic model showed that eltrombopag dominates romiplostim but is not costeffective versus rituximab. OBJECTIVES: Uncertainty regarding the effectiveness of tyrosine kinase inhibitors (TKIs) for treatment of chronic myeloid leukemia (CML) has resulted in diffi culty for some appraisal committees to recommend second-line TKIs. Implementation of pharmacogenomic-based diagnostics may facilitate individualized treatment with TKIs and improve overall treatment effectiveness. The objective of this economic evaluation was to estimate the potential cost-effectiveness of a companion diagnostic that predicts treatment response in CML patients eligible for dasatinib and nilotinib. METHODS: A decision analytic model was created to assess the cost-effectiveness of individualized treatment with dasatinib and nilotinib using a companion diagnostic test relative to current care (i.e., treat all patients with dasatinib until progression or no response, then treat with nilotinib). Transition probabilities and utility values were taken from published RCTs. The cost analysis included costs of treatment, response monitoring and the companion diagnostic. Scenario analyses were conducted to assess the impact of unavailable or highly uncertain values. RESULTS: Total costs and effects for the base-case analysis were c99,011 and 1.84 progression-free LYs (PF-LYs) and 1.63 QALYs with the companion diagnostic strategy after a 2-year time horizon. In the current care situation, total costs and effects were c100,904 and 1.74 PF-LYs and 1.61 QALYs. The companion diagnostic was the dominant strategy with a savings of approximately c4,000/PF-LY or c2,000/QALY. Scenario analyses revealed that the cost-effectiveness of the companion diagnostic is sensitive to time to response, time to progression and comparative effectiveness between dasatinib and nilotinib. CONCLU-SIONS: Treatment of CML patients eligible for second-line TKIs using a companion diagnostic may be cost-effective. More precise estimates for uncertain or unavailable parameters should be incorporated when available. This case demonstrates the use of economic evaluation methods at early stages of technology development for internal decision-making and communicating the potential value of pharmacogenomic-based diagnostics to stakeholders. OBJECTIVES: To assess the cost-effectiveness of tapentadol compared to oxycodone and morphine as 1 st line strong opioid therapy in chronic non-cancer pain (CNCP) patients in Sweden. METHODS: A Markov transition state model over one year with cycle times of one month was built. Four health states were defi ned: 'occurrence of adverse events (AEs) with need for medical treatment', 'withdrawal due to AEs', 'response to therapy' and 'death'. If patients did not adequately respond to tapentadol or comparators or withdrew, switching to alternative 2 nd line opioid (oxycodone, morphine or transdermal fentanyl) was considered. After initiating 3 rd line therapy, patients could stay on this therapy or die according to morbidity rate. Data regarding effi cacy, tolerability and utility values (EQ-5D) were derived from clinical trials and published literature. Switch rates to subsequent opioid therapies and resource consumption were estimated by clinical experts. Costs were calculated from the societal perspective. Direct costs were calculated based on offi cial Swedish prices/tariffs, indirect costs were calculated based on fi gures obtained from the literature and current wage rates. Costs and benefi ts were not discounted in base-case calculation. Impact of selected parameters on the results was evaluated in one-way sensitivity analyses (OWSA). RESULTS: Mean annual total costs per patient amount to 242,583 SEK (Swedish krona) for tapentadol vs. 247,813 SEK for oxycodone and 246,093 SEK for morphine. Tapentadol generates 0.4712 QALYs compared to 0.4518 QALYs for oxycodone and 0.4535 QALYs for morphine. More QALYs generated in the model refl ect tapentadol's better tolerability profi le than comparators. Cost parameter comprising physician visits, co-medications and non-drug therapy costs revealed highest impact in OWSA. CONCLUSIONS: Tapentadol, once approved, will generate more QALYs at lower costs than oxycodone and morphine. Tapentadol appears to be the favourable treatment option in the 1 st line therapy of CNCP patients in Sweden from a societal perspective. OBJECTIVES: To evaluate the cost-effectiveness of duloxetine for the management of fi bromyalgia assessed from the perspective of a health care payer in the United States. METHODS: A Markov model was used to evaluate the economic and clinical advantages in controlling fi bromyalgia pain symptoms, considering duloxetine as an additional treatment option. The standard treatment sequence was defi ned based on clinical guidelines including tricyclic antidepressants (TCAs), second-generation antidepressants (based on SNRIs), anticonvulsants, and opioid therapies. The model included 2 levels of pain response (a ≥30% and ≥50% change from baseline, using a standard 11-point severity scale). Clinical effi cacy and discontinuation data were taken from a systematic literature review and mixed treatment comparison, including both placebo and active controlled trials. Utility data were linked to pain severity using trial-based EQ5D data. Discounting was applied at 3.0% per year. RESULTS: The introduction of duloxetine resulted in additional symptom-controlled months (SCMs), defi ned as the amount of time at a ≥30% response level, and quality-adjusted life-years (QALYs), over a 2-year time horizon. First-line treatment resulted in an additional 665 SCMs and 12.3 QALYs, with a cost of $582,911 ($877 per SCM and $47,560 per QALY). Second-line treatment resulted in an additional 460 SCMs and 8.7 QALYs, with a cost of $143,752 ($312 per SMC and $16,565 per QALY). a costeffectiveness frontier analysis suggested that second-line duloxetine is likely to be the most cost-effective option, however, in sensitivity analyses, the cost-effectiveness of fi rst-line duloxetine improved when assumptions around continued treatment switching for long-term drop-outs were relaxed. CONCLUSIONS: There is currently a signifi cant unmet need for patients with poorly controlled fi bromyalgia where pain is a predominant symptom. These analyses show that the introduction of duloxetine into the standard treatment sequence for fi bromyalgia can provide additional patient benefi ts, which are cost-effective when compared to commonly adopted thresholds. OBJECTIVES: The objective of this analysis was to understand the economic consequences of different products in primary prophylaxis in severe hemophilia A patients. Miners ' (2002, 2009) hemophilia economic Markov model was revised to compare two different factor VIII products-a full-length recombinant FVIII (Advate) and a B domain-deleted recombinant FVIII (BDDrFVIII) (Refacto AF). Based on documented differences in half life in a pharmacokinetic cross-over license study [1] with results submitted to EMA[2], this research evaluated the amount of clotting factor required to maintain the patient factor VIII trough levels above 1%. If a product has a shorter half-life, more clotting factor is required to prevent factor VIII levels falling below the minimum trough level. METHODS: The same basic model structure of Miners' hemophilia economic Markov model was used to analyze the effects of differences in half-life in an Italian economic country setting, full-length recombinant FVIII (Advate) half-life 13.3 hours at a list price of c0.75 per IU versus BDDrFVIII (Refacto AF) half-life 11.2 hours at a list price of c0.69 per IU. The model considers the amount of factor required to prevent trough clotting factor levels from falling below 1%. RESULTS: The analysis estimated that the mean expected, discounted lifetime (70 years) cost of primary prophylaxis in a severe hemophilia A patient was c0.88 million less using full length recombinant FVIII (Advate) when compared to a BDDrFVIII (Refacto AF), assuming a 2.1 hour shorter half-life; i.e. equal to over c12,500 in cost savings per patient per year. CONCLUSIONS: This analysis shows that prophylaxis therapy using full-length recombinant FVIII (Advate) may be cost saving compared to
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